OnKure Therapeutics, Inc. $OKUR Shares Sold by Cantor Fitzgerald L. P.

Cantor Fitzgerald L. P. cut its stake in shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) by 26.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 491,863 shares of the company’s stock after selling 177,676 shares during the quarter. Cantor Fitzgerald L. P.’s holdings in OnKure Therapeutics were worth $1,353,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. XTX Topco Ltd bought a new stake in shares of OnKure Therapeutics in the 2nd quarter worth approximately $25,000. Rangeley Capital LLC bought a new position in OnKure Therapeutics during the 2nd quarter worth $71,000. GSA Capital Partners LLP grew its stake in OnKure Therapeutics by 172.1% during the 3rd quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock worth $163,000 after buying an additional 37,459 shares during the last quarter. Prosight Management LP increased its position in OnKure Therapeutics by 67.8% in the third quarter. Prosight Management LP now owns 267,959 shares of the company’s stock worth $737,000 after buying an additional 108,267 shares during the period. Finally, Shay Capital LLC increased its position in OnKure Therapeutics by 17.4% in the third quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock worth $2,524,000 after buying an additional 135,888 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on OKUR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of OnKure Therapeutics in a report on Monday, December 22nd. HC Wainwright lowered their price target on shares of OnKure Therapeutics from $34.00 to $27.00 and set a “buy” rating for the company in a research report on Monday. Finally, Wall Street Zen upgraded shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, OnKure Therapeutics presently has an average rating of “Hold” and a consensus target price of $27.00.

OnKure Therapeutics Price Performance

Shares of OKUR stock opened at $4.01 on Thursday. OnKure Therapeutics, Inc. has a 12-month low of $1.70 and a 12-month high of $5.28. The firm has a market capitalization of $54.34 million, a price-to-earnings ratio of -0.91 and a beta of 0.45. The business has a 50 day simple moving average of $2.91 and a 200 day simple moving average of $2.89.

OnKure Therapeutics (NASDAQ:OKUR) last announced its earnings results on Monday, March 9th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.16. On average, equities analysts anticipate that OnKure Therapeutics, Inc. will post -4.05 EPS for the current fiscal year.

OnKure Therapeutics Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.